Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02796716 · ClinicalTrials.gov registry record

Study of Accuracy of New Diagnostic Technology to Guide Rapid Antibiotic Treatment for Serious Infections

A clinical trial, sponsored by Denver Health and Hospital Authority.

Completed
Registry status
2,102
Enrollment target

NCT02796716 is a clinical trial that has completed, run by Denver Health and Hospital Authority. The registered enrollment target is 2,102 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02796716 has completed, sponsored by Denver Health and Hospital Authority.

COMPLETED
Registry status
2,102 participants
Enrollment target

Study Summary

This research will test a new ultra-rapid technology (called ID/AST Accelerate system) that uses a digital microscope to identify bacteria based on their growth patterns. This method does not have to wait for bacteria to grow in a lab. The new method can identify the type of bacteria within 2 hours of receiving a specimen. The new method also shows the effect of selected antibiotics on the bacteria including multidrug resistant bacteria so that doctors know within 6 hours from specimen collection which antibiotic kills the bacteria. To check the accuracy, speed and impact of the new method on antibiotic prescribing, investigators are proposing a study with two parts; The first part will test the accuracy and speed of the results obtained by the new method. The second part will test if having the results from the new method early would change the antibiotics prescribed to a patient in a simulation experiment. An independent infectious disease physician will be shown the results from the new method and asked if the results were accurate, would it change the antibiotic treatment for the patient.

Interventions

  • DEVICE Testing on new technology called Accelerate ID/AST system

Trial Details

FieldValue
Enrollment Target 2,102 participants
Start Date 2015-07
Est. Completion 2016-12

What the Registry Record Tells You About NCT02796716

The ClinicalTrials.gov registry entry for NCT02796716 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Denver Health and Hospital Authority, which has 73 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Testing on new technology called Accelerate ID/AST system is the first listed.

NCT02796716 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02796716 about?

NCT02796716 is a clinical study titled "Study of Accuracy of New Diagnostic Technology to Guide Rapid Antibiotic Treatment for Serious Infections". This research will test a new ultra-rapid technology (called ID/AST Accelerate system) that uses a digital microscope to identify bacteria based on their growth patterns. This method does not have to wait for bacteria to grow in a lab. The new method can identify the type of bacteria within 2 hours ...

What is the current status of trial NCT02796716?

This trial is currently completed. The enrollment target is 2,102 participants. The study started on 2015-07. Estimated completion is 2016-12.

What interventions are being tested in trial NCT02796716?

The interventions under investigation include: Testing on new technology called Accelerate ID/AST system (DEVICE).

Who is sponsoring clinical trial NCT02796716?

This trial is sponsored by Denver Health and Hospital Authority, which has 73 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.